Paradigm hits the road with new inflammation treatment

Paradigm Biopharmaceutical’s nonclinical and clinical data have been accepted for presentations at major international conferences.

The company will showcase its late-stage development of an injectable pentosan polysulfate sodium (PPS) for the treatment of diseases where inflammation plays a significant pathogenic role, such as osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Three medical conferences have accepted presentations on injectable pentosan polysulfate sodium (iPPS) for treating musculoskeletal disorders.

Dr. Ravi Krishnan will speak virtually at the Symposium on Glycosaminoglycans, while Paradigm’s clinical and nonclinical studies on osteoarthritis will be presented at the American College of Rheumatology Convergence Conference.

“The acceptance of abstracts, posters and oral presentations at critical conferences is significant as it is yet another form of peer review validation within arthritis and pain management, scientific and clinical communities,” Paradigm Managing Director, Mr Paul Rennie, said.

“Such validation is expected to support product adoption amongst prescribing physicians, once on the market.”

PAR.AX

PARA BIO FPO [PAR]

ASX

$0.315

$0.005

1.56%

PARA BIO FPO [PAR]

Sector: Healthcare

Industry: Biotechnology

Employees:

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.